GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Keros Therapeutics
The stock of Keros Therapeutics, a biotech focused on treating blood and musculoskeletal disorders, reflects the potential of its scientific platform. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Specialized pharma
Keros Therapeutics is a biopharmaceutical company developing drugs for the treatment of hematological and musculoskeletal diseases. We classify it as a "Specialty Pharmaceutical." The chart below shows how investors value companies operating in niche but important areas of medicine.
Broad Market Index - GURU.Markets
Keros Therapeutics is a biopharmaceutical company developing drugs for the treatment of hematological and musculoskeletal diseases. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
KROS - Daily change in the company's share price Keros Therapeutics
Shares of Keros, a biopharmaceutical company, are highly volatile. change_co tracks investor reactions to news about clinical trials of its drugs. This metric is the basis for advanced biotech risk analysis formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Specialized pharma
Keros Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with KROS, which focuses on rare disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Keros is a biopharmaceutical company specializing in drugs for rare diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Keros's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Keros Therapeutics
Keros is a biotechnology company specializing in the treatment of rare diseases. Its year-over-year performance reflects the commercial success of its drugs and investor confidence in its R&D platform, which is focused on new breakthrough drugs.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Keros Therapeutics, Inc. is a clinical-stage biotechnology company developing drugs for the treatment of blood and musculoskeletal disorders. Its stock performance is entirely dependent on clinical trial results. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Keros Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Keros Therapeutics
Golden, a diversified casino and tavern operator, has monthly fluctuations that reflect both tourism to its Nevada casinos and the state of the local economy, which impacts its tavern revenues. This makes it vulnerable to a variety of factors.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
Keros Therapeutics develops drugs to treat blood and musculoskeletal disorders. This is a highly competitive area of biotechnology. The sector's performance reflects general investor sentiment toward science-intensive companies whose value depends almost entirely on the success of clinical trials. The chart below provides context for assessing Keros's risks and prospects.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of hematological and neuromuscular diseases. The company's future depends on the success of its clinical trials. The broader market chart serves only as a backdrop to understand how scientific data and trial progress have impacted its stock price.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Keros Therapeutics
Keros Therapeutics is a biotech company developing drugs for the treatment of blood and musculoskeletal disorders. Its weekly stock price is volatile and depends on clinical trial news.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Keros Therapeutics is a biotech company. Comparing its weekly performance to the broader biotech sector only highlights its uniqueness. The chart shows how news about clinical trials of its drugs drives share prices independently of overall trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Keros, a biotech company, live in a world of their own. Their performance is driven by clinical trial data. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
KROS - Market capitalization of the company Keros Therapeutics
Keros Therapeutics' market cap reflects the development of drugs targeting the TGF-β protein family for the treatment of rare blood and musculoskeletal disorders. This biotech's stock price reflects investor expectations for its scientific platform and early clinical trial data.
KROS - Share of the company's market capitalization Keros Therapeutics within the market segment - Specialized pharma
Keros Therapeutics is a biotech company developing drugs to treat blood and musculoskeletal disorders. Its market share reflects the potential of its scientific platform. The chart below shows how the market assesses its chances of developing new treatments for rare and severe diseases.
Market capitalization of the market segment - Specialized pharma
Keros Therapeutics develops drugs for the treatment of blood and musculoskeletal disorders. The chart below shows the overall market capitalization of the specialty pharmaceuticals sector. It provides context for evaluating a company operating in complex areas with unmet medical needs.
Market capitalization of all companies included in a broad market index - GURU.Markets
This shows the science that's trying to "fix" the body's signaling pathways. Keros Therapeutics develops drugs to treat rare blood and musculoskeletal diseases. Its volatile market cap reflects progress in clinical trials. This is a visualization of fundamental biology in action.
Book value capitalization of the company, segment and market as a whole
KROS - Book value capitalization of the company Keros Therapeutics
Keros Therapeutics' book value is determined by its scientific platform for discovering drugs targeting the TGF-β protein family and its financial reserves. This represents cutting-edge scientific capital for treating rare diseases. The chart shows how the biotech company accumulates and spends funds to develop its unique therapeutic approaches.
KROS - Share of the company's book capitalization Keros Therapeutics within the market segment - Specialized pharma
Keros Therapeutics is a biotech company developing drugs for the treatment of blood and musculoskeletal diseases. Its assets are intellectual property. The chart shows a minimal share of physical assets, which is typical for an R&D company.
Market segment balance sheet capitalization - Specialized pharma
Developing drugs for rare diseases, like Keros's, is a knowledge-intensive but relatively "easy" business at the R&D stage. Its value lies in its patents. Compared to the capital-intensive pharmaceutical sector, the company's model doesn't require the ownership of large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Keros Therapeutics' assets are not factories, but laboratories and capital focused on developing drugs for rare blood and musculoskeletal diseases. The book value reflects the financial resources available for clinical trials. The chart illustrates the scale of this biotech company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Keros Therapeutics
For Keros, a company developing drugs for rare diseases, market capitalization reflects its belief in its science. Its ratio to book value (its cash value) reflects the premium the market pays for the potential of its drug candidates to become new standards of care.
Market to book capitalization ratio in a market segment - Specialized pharma
Keros Therapeutics is a biotech company developing drugs to treat blood and musculoskeletal disorders. Its high valuation on this chart reflects its scientific platform and potential to create new treatment standards.
Market to book capitalization ratio for the market as a whole
Keros Therapeutics is a biotech company developing drugs for the treatment of blood and musculoskeletal disorders. Its valuation is based on the potential of its scientific platform. This metric illustrates how the market values clinical-stage biotech companies, whose value can increase exponentially if clinical trials are successful.
Debts of the company, segment and market as a whole
KROS - Company debts Keros Therapeutics
Keros Therapeutics, a biotech company developing drugs for rare diseases, funds its clinical programs through raised capital. This graph reflects its need for long-term investments to bring its innovative developments from the laboratory to the patient.
Market segment debts - Specialized pharma
Keros Therapeutics is a clinical-stage biotech company focused on developing drugs for the treatment of blood and musculoskeletal disorders. This chart shows how the company funds its research and clinical trials, raising capital from investors to advance its drug candidates through complex development stages.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Keros Therapeutics
Keros Therapeutics is a biopharmaceutical company developing drugs to treat blood and musculoskeletal disorders. The path from a scientific idea to an approved drug is long, expensive, and risky. This chart illustrates the company's reliance on debt to finance its cutting-edge, yet high-risk, clinical programs.
Market segment debt to market segment book capitalization - Specialized pharma
Keros Therapeutics is a biopharmaceutical company developing drugs for the treatment of blood and musculoskeletal disorders. Clinical trials require significant investment. This chart shows how the company finances its operations, comparing its debt structure to the broader biotech sector.
Debt to book value of all companies in the market
Keros Therapeutics is a biopharmaceutical company developing drugs to treat blood and musculoskeletal disorders. Biotechnology is a high-risk, high-investment industry. How heavily is Keros leveraged? This chart of total market debt provides context for assessing its financial vulnerability.
P/E of the company, segment and market as a whole
P/E - Keros Therapeutics
Keros Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of blood and musculoskeletal disorders. This chart shows how investors value its research. The valuation is volatile and depends on news about the progress of clinical trials and the potential of its candidates.
P/E of the market segment - Specialized pharma
Keros Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of drugs for the treatment of hematological and musculoskeletal diseases. This chart shows the average valuation for the sector, providing investors with context for assessing the scientific potential and risks associated with Keros' portfolio.
P/E of the market as a whole
Keros Therapeutics is a biopharmaceutical company developing drugs for the treatment of blood and musculoskeletal disorders. Valuing such companies is a bet on the success of clinical trials. Does comparing this chart reveal the extent to which Keros investors are ignoring the broader market picture, betting solely on its scientific potential?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Keros Therapeutics
Keros Therapeutics is a biopharmaceutical company developing drugs for the treatment of blood and musculoskeletal disorders. This chart shows market expectations for the success of its clinical programs. Future revenue depends on regulatory approvals and the commercial potential of its innovative drugs.
%20P%2FE%20Keros%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Keros-Therapeutics&v=1772641367382 "Chart of the company's future (projected) P/E Keros Therapeutics")
Future (projected) P/E of the market segment - Specialized pharma
Keros Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of blood and musculoskeletal disorders. Its approach is based on the regulation of the TGF-β protein family. The chart shows forecasts for the pharmaceutical industry, allowing for a comparison of how the market views Keros's scientific platform and the potential of its leading drug candidates.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772641367387 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Keros Therapeutics is a biopharmaceutical company developing drugs for the treatment of blood and musculoskeletal disorders. The company's valuation is based on the potential of its scientific research. This overall risk appetite chart shows how willing investors are to fund fundamental research in biotech.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772641367388 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Keros Therapeutics
Keros Therapeutics is a biopharmaceutical company developing drugs for the treatment of blood and musculoskeletal disorders. Being in the clinical stage, it has no commercial revenue. This chart illustrates the financial side of biotechnology, where significant losses are investments in potentially breakthrough drugs.
Profit of companies in the market segment - Specialized pharma
Keros Therapeutics is a biopharmaceutical company developing drugs for the treatment of blood and musculoskeletal disorders. This graph, which reflects profitability in the pharmaceutical sector, highlights the investment climate. Their scientific approach targets the regulation of TGF-β proteins, opening up new opportunities for the treatment of rare and severe diseases.
Overall market profit
Keros Therapeutics develops drugs for the treatment of blood and musculoskeletal disorders. Like many clinical-stage biotechs, its value is determined by the potential of its research and development. This graph of overall market returns reflects the investment climate. During growth periods, investors are more inclined to fund companies with high risk but also high potential.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Keros Therapeutics
Keros Therapeutics is a biopharmaceutical company developing drugs for the treatment of blood and musculoskeletal disorders by targeting the TGF-β protein family. This graph represents analyst expectations for the success of clinical trials and the potential of their innovative approaches for treating rare and severe diseases.
%20profit%20of%20the%20company%20Keros%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Keros-Therapeutics&v=1772641367400 "Graph of future (projected) profit of the company Keros Therapeutics")
Future (predicted) profit of companies in the market segment - Specialized pharma
Keros Therapeutics is a biopharmaceutical company developing drugs for the treatment of hematological and musculoskeletal diseases. Its future depends on the success of clinical trials. This biotech chart reflects overall investor sentiment and their expectations for companies developing new classes of drugs for complex diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772641367401 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
Keros Therapeutics, a biopharmaceutical company, develops drugs for the treatment of blood and musculoskeletal disorders. Its future is determined by scientific advances. The overall profit forecast, reflected in this chart, influences the overall investment climate and the market's willingness to finance innovative biotechnologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772641367401 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Keros Therapeutics
Keros Therapeutics is a biopharmaceutical company focused on the discovery and development of drugs for the treatment of blood and musculoskeletal disorders. For a clinical-stage company, this chart is key. It shows how investors evaluate its scientific platform and future sales potential, placing their bets on a breakthrough in the treatment of rare diseases.
P/S market segment - Specialized pharma
Keros Therapeutics is a biopharmaceutical company developing drugs for the treatment of blood and musculoskeletal disorders. The company's valuation is based on the future potential of its clinical programs. This chart, which reflects the average valuation in the biotech industry, helps investors understand how expectations for Keros's pipeline align with overall industry trends.
P/S of the market as a whole
Keros Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of blood and musculoskeletal disorders. This chart, which reflects market revenue estimates, serves as a benchmark for Keros's expectations. It demonstrates the value investors place on the company's scientific platform and its potential to create new treatments for patients.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Keros Therapeutics
Keros Therapeutics is a clinical-stage biotechnology company focused on developing drugs for the treatment of blood and musculoskeletal disorders. This chart reflects investor expectations for the future success of its candidates, which may offer new approaches to treating rare and serious diseases.
%20P%2FS%20Keros%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Keros-Therapeutics&v=1772641367403 "The graph of the company's future (projected) P/S Keros Therapeutics")
Future (projected) P/S of the market segment - Specialized pharma
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of new drugs for the treatment of hematological and musculoskeletal diseases. This chart reflects average revenue expectations in the biotech sector. It provides an insight into how highly the market values Keros Therapeutics' scientific potential.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772641367404 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
Keros Therapeutics is a biopharmaceutical company developing treatments for blood and musculoskeletal disorders. This chart shows investor expectations for revenue growth. Keros' success in developing new treatments could significantly improve patients' lives and open new markets, fueling investor optimism in the biotech sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772641367404 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Keros Therapeutics
This chart shows the revenue of Keros Therapeutics, a clinical-stage biopharmaceutical company developing drugs to treat blood and musculoskeletal disorders. At this stage, its revenue, if any, is generated through collaboration fees, reflecting research progress rather than sales.
Sales of companies in the market segment - Specialized pharma
Keros Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of hematological and musculoskeletal diseases. This graph shows the potential market for its products. Keros' innovative approaches to regulating TGF-β proteins could lead to the creation of a new class of drugs for the treatment of rare and severe diseases.
Overall market sales
Keros Therapeutics is a biopharmaceutical company focused on treating blood and musculoskeletal disorders. Its prospects depend on the success of clinical trials. The overall economic situation, shown in this chart, affects the availability of capital for funding long-term biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Keros Therapeutics
Keros Therapeutics is a biopharmaceutical company developing drugs for the treatment of hematological and musculoskeletal diseases. Its revenue forecast is based on expectations of successful clinical trials. The graph reflects analysts' confidence in its scientific platform and developments.
%20sales%20of%20the%20company%20Keros%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Keros-Therapeutics&v=1772641367413 "Schedule of future (projected) sales of the company Keros Therapeutics")
Future (projected) sales of companies in the market segment - Specialized pharma
Keros Therapeutics is a biopharmaceutical company focused on the discovery and development of new drugs for the treatment of blood and musculoskeletal disorders. The company leverages a deep understanding of the biology of the TGF-β protein family. This graph shows the outlook for the entire pharmaceutical market, where Keros strives to offer innovative therapies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772641367416 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Keros Therapeutics is a biopharmaceutical company developing drugs for the treatment of blood and musculoskeletal disorders. Its value is determined by the potential of its scientific developments. This chart reflects overall market sentiment, but for Keros, progress in clinical trials, which could lead to the creation of new treatment standards in its field, is key.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772641367423 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Keros Therapeutics
Keros Therapeutics is a biotech company developing drugs for the treatment of blood and musculoskeletal disorders. Being in the clinical stage, it incurs significant research expenses. This chart shows its net losses—investments in research aimed at developing a new class of drugs that regulate the production of growth factors.
Market segment marginality - Specialized pharma
Keros Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of drugs for the treatment of hematological and musculoskeletal diseases. Profitability is a long-term goal. This chart reflects clinical trial costs. Investors evaluate it in the context of the company's potential to treat rare and complex diseases.
Market marginality as a whole
Keros Therapeutics is a biopharmaceutical company developing drugs to treat blood and musculoskeletal disorders. They focus on proteins that regulate tissue growth and repair. This overall profitability curve is irrelevant to them. Their value and future depend solely on the results of clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Keros Therapeutics
Keros Therapeutics is a clinical-stage biotech company developing drugs for the treatment of blood and musculoskeletal disorders. Its small team is focused on R&D. Growth on this chart will indicate progress in clinical trials and the expansion of its scientific capabilities.
Share of the company's employees Keros Therapeutics within the market segment - Specialized pharma
Keros Therapeutics is a biopharmaceutical company developing drugs for the treatment of blood and musculoskeletal diseases. This chart shows its share of the total number of researchers in these areas. The growth in this percentage indicates progress in clinical trials and the expansion of the scientific team working on the development of a new class of therapeutics.
Number of employees in the market segment - Specialized pharma
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of hematological and musculoskeletal diseases. This chart reflects employment trends in the specialty pharmaceuticals sector. The growing number of scientists and clinicians here signals progress in clinical programs and the potential for new treatments.
Number of employees in the market as a whole
Keros Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of blood and musculoskeletal disorders. Its approach is based on the regulation of a specific protein family. This graph illustrates how advanced biological research can lead to the creation of new classes of drugs and stimulate employment growth in biotechnology.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Keros Therapeutics (KROS)
Keros Therapeutics is a biotech company specializing in drugs for the treatment of blood and musculoskeletal diseases. This chart is a classic example of intellectual capital valuation. The company's value is based on market expectations for its scientific platform. The chart shows the high future value the market attributes to these developments, per scientist.
%20of%20the%20company%20Keros%20Therapeutics%20(KROS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Keros-Therapeutics-KROS&v=1772641367454 "Chart of market capitalization per employee (in thousands of dollars) of the company Keros Therapeutics (KROS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Keros Therapeutics is a biotech company developing drugs for the treatment of blood and musculoskeletal diseases. Its valuation is based on the potential of its scientific platform. This chart demonstrates the high valuation of intellectual capital and future prospects based on a small team of scientists.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772641367464 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Keros Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of blood and musculoskeletal diseases. The chart reflects its scientific potential. The company's entire value is derived from the hope of successful clinical trials. This indicator demonstrates the value the market places on the work of each scientist.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772641367469 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Keros Therapeutics (KROS)
Keros Therapeutics is a clinical-stage biotech company specializing in the development of drugs for the treatment of blood and musculoskeletal disorders. This is a science-intensive R&D company. This chart reflects the high stakes: it shows the investment required for each scientist working on a potential breakthrough drug.
%20Chart%20Keros%20Therapeutics%20(KROS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Keros-Therapeutics-KROS&v=1772641367470 "Company Profit Per Employee (in thousands of dollars) Chart Keros Therapeutics (KROS)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Keros Therapeutics (KROS) is a clinical-stage biotechnology company developing drugs for the treatment of blood and musculoskeletal disorders. This metric (loss per employee) reflects the high costs of R&D and clinical trials.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772641367474 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Keros Therapeutics is a clinical-stage biotech company specializing in the treatment of blood and musculoskeletal disorders. It is an R&D company and is not profitable. This chart shows the company's capital burn rate: the operating loss per research team developing the new drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772641367475 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Keros Therapeutics (KROS)
Keros Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of blood and musculoskeletal disorders. This chart reflects the progress of monetizing its research. Revenue at this stage likely comes from partnerships, and the growth in revenue per employee is an indicator of interest in its developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Keros-Therapeutics-KROS&v=1772641367484 "Sales chart per company employee Keros Therapeutics (KROS)")
Sales per employee in the market segment - Specialized pharma
Keros Therapeutics (KROS) is a biotech company developing drugs for blood and musculoskeletal disorders. This chart shows how productive their research team is. It measures revenue (likely from partnerships) per researcher, comparing them to other companies in the segment.
Sales per employee for the market as a whole
Keros Therapeutics (KROS) is a clinical-stage biotech company specializing in drugs for the treatment of blood and musculoskeletal disorders. The company does not yet have commercial revenue. This chart illustrates a typical R&D situation: the research team generates data and patents, but not revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Keros Therapeutics (KROS)
Keros Therapeutics is a biotech company developing drugs to treat blood and musculoskeletal disorders. The bearish sentiment shown in this chart reflects investor bets that its early- and mid-stage candidates will fail to demonstrate efficacy in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Keros-Therapeutics-KROS&v=1772641367493 "Short Shares Chart for the Company Keros Therapeutics (KROS)")
Shares shorted by market segment - Specialized pharma
Keros Therapeutics is a biotech company developing drugs for the treatment of blood and musculoskeletal disorders. This indicator measures pessimism. "Shorts" here represent a bet that their scientific platform will fail to produce successful candidates that will pass clinical trials.
Shares shorted by the overall market
Keros Therapeutics (KROS) is a clinical-stage biotech focused on treating rare blood and musculoskeletal diseases. This chart measures the overall level of fear in the market. When it rises, investors flee speculative assets. KROS shares could fall simply due to the general "risk-off" sentiment, even if their science is successful.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Keros Therapeutics (KROS)
Keros Therapeutics is a biotech whose stock fluctuates between trial press releases. This chart measures the strength and speed of investors' emotional reactions to this news. It helps identify when enthusiasm for their drug data (overbought) or disappointment (oversold) becomes excessive.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Keros-Therapeutics-KROS&v=1772641367496 "RSI 14 indicator chart for the company's stock Keros Therapeutics (KROS)")
RSI 14 Market Segment - Specialized pharma
Keros Therapeutics is a biotech company specializing in developing drugs to treat rare hematological (blood) and musculoskeletal diseases. This chart reflects the collective momentum across the entire specialty pharmaceutical sector. It helps us understand whether the entire segment is overheated by expectations of breakthroughs, or whether KROS's performance is isolated.
RSI 14 for the overall market
Keros Therapeutics (KROS) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KROS (Keros Therapeutics)
Keros Therapeutics is a biotech company developing drugs for the treatment of blood and musculoskeletal disorders. Their approach targets the regulation of proteins in the TGF-beta family. This chart shows the analysts' average 12-month forecast, representing their collective speculative bet on the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KROS-Keros-Therapeutics&v=1772641367508 "A chart showing analyst consensus forecasts for the expected stock price. KROS (Keros Therapeutics)")
The difference between the consensus estimate and the actual stock price KROS (Keros Therapeutics)
Keros (KROS) is a clinical-stage biotech focused on rare blood diseases (anemia, MDS) and musculoskeletal disorders. This is an R&D bet on the company's scientific platform. This chart shows the difference between the consensus estimate and the price, reflecting analysts' confidence in the potential of its R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KROS-Keros-Therapeutics&v=1772641367520 "A chart showing the difference between the consensus forecast and the actual stock price. KROS (Keros Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Keros Therapeutics (KROS) is a biotech company developing next-generation drugs for the treatment of blood disorders (anemia) and musculoskeletal disorders. This chart shows general expectations for the specialty pharmaceutical sector. It reflects experts' confidence in the success of this innovative R&D platform.
Analysts' consensus forecast for the overall market share price
Keros Therapeutics (KROS) is an R&D biotech focused on rare blood and muscle diseases. They're burning cash. This chart, reflecting the economic consensus, reflects their risk appetite. If the consensus is negative (downturn), investors flee cash-burning, pre-profit biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Keros Therapeutics
Keros is a biotech company focused on growth pathways. They develop drugs (based on ligand traps) for the treatment of rare blood disorders (anemia) and musculoskeletal disorders. This chart is a pure indicator of their platform. It likely aggregates their clinical trial data and market confidence in their scientific approach to regulating growth proteins.
AKIMA Market Segment Index - Specialized pharma
Keros (KROS) is a clinical-stage biotech focused on rare diseases; the company develops innovative drugs (TGF-β inhibitors) for the treatment of rare blood and muscle disorders. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this R&D platform (KROS) differentiate it from the average pharma company?
The AKIM Index for the overall market
Keros Therapeutics is a biotech company developing treatments for blood and muscle diseases (TGF-beta). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical-stage research story compares to overall economic trends impacting the healthcare sector and risk appetite.
